Therapeutic use of botulinum toxin in neurorehabilitation

Research output: Contribution to journalArticle

Abstract

The botulinum toxins (BTX), type A and type B by blocking vesicle acetylcholine release at neuro-muscular and neuro-secretory junctions can result efficacious therapeutic agents for the treatment of numerous disorders in patients requiring neuro-rehabilitative intervention. Its use for the reduction of focal spasticity following stroke, brain injury, and cerebral palsy is provided. Although the reduction of spasticity is widely demonstrated with BTX type A injection, its impact on the improvement of dexterity and functional outcome remains controversial. The use of BTX for the rehabilitation of children with obstetrical brachial plexus palsy and in treating sialorrhea which can complicate the course of some severe neurological diseases such as amyotrophic lateral sclerosis and Parkinsons disease is also addressed. Adverse events and neutralizing antibodies formation after repeated BTX injections can occur. Since impaired neurological persons can have complex disabling feature, BTX treatment should be viewed as adjunct measure to other rehabilitative strategies that are based on the individuals residual ability and competence and targeted to achieve the best functional recovery. BTX therapy has high cost and transient effect, but its benefits outweigh these disadvantages. Future studies must clarify if this agent alone or adjunctive to other rehabilitative procedures works best on functional outcome.

Original languageEnglish
Article number802893
JournalJournal of Toxicology
Volume2012
DOIs
Publication statusPublished - 2012

Fingerprint

Botulinum Toxins
Therapeutic Uses
Type A Botulinum Toxins
Sialorrhea
Injections
Aptitude
Brachial Plexus
Amyotrophic Lateral Sclerosis
Cerebral Palsy
Therapeutics
Neutralizing Antibodies
Paralysis
Patient rehabilitation
Mental Competency
Brain Injuries
Acetylcholine
Antibody Formation
Parkinson Disease
Brain
Rehabilitation

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

Therapeutic use of botulinum toxin in neurorehabilitation. / Intiso, Domenico.

In: Journal of Toxicology, Vol. 2012, 802893, 2012.

Research output: Contribution to journalArticle

@article{747f2ff1ccaf4206bf075ee9fad778ea,
title = "Therapeutic use of botulinum toxin in neurorehabilitation",
abstract = "The botulinum toxins (BTX), type A and type B by blocking vesicle acetylcholine release at neuro-muscular and neuro-secretory junctions can result efficacious therapeutic agents for the treatment of numerous disorders in patients requiring neuro-rehabilitative intervention. Its use for the reduction of focal spasticity following stroke, brain injury, and cerebral palsy is provided. Although the reduction of spasticity is widely demonstrated with BTX type A injection, its impact on the improvement of dexterity and functional outcome remains controversial. The use of BTX for the rehabilitation of children with obstetrical brachial plexus palsy and in treating sialorrhea which can complicate the course of some severe neurological diseases such as amyotrophic lateral sclerosis and Parkinsons disease is also addressed. Adverse events and neutralizing antibodies formation after repeated BTX injections can occur. Since impaired neurological persons can have complex disabling feature, BTX treatment should be viewed as adjunct measure to other rehabilitative strategies that are based on the individuals residual ability and competence and targeted to achieve the best functional recovery. BTX therapy has high cost and transient effect, but its benefits outweigh these disadvantages. Future studies must clarify if this agent alone or adjunctive to other rehabilitative procedures works best on functional outcome.",
author = "Domenico Intiso",
year = "2012",
doi = "10.1155/2012/802893",
language = "English",
volume = "2012",
journal = "Journal of Toxicology",
issn = "1687-8191",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Therapeutic use of botulinum toxin in neurorehabilitation

AU - Intiso, Domenico

PY - 2012

Y1 - 2012

N2 - The botulinum toxins (BTX), type A and type B by blocking vesicle acetylcholine release at neuro-muscular and neuro-secretory junctions can result efficacious therapeutic agents for the treatment of numerous disorders in patients requiring neuro-rehabilitative intervention. Its use for the reduction of focal spasticity following stroke, brain injury, and cerebral palsy is provided. Although the reduction of spasticity is widely demonstrated with BTX type A injection, its impact on the improvement of dexterity and functional outcome remains controversial. The use of BTX for the rehabilitation of children with obstetrical brachial plexus palsy and in treating sialorrhea which can complicate the course of some severe neurological diseases such as amyotrophic lateral sclerosis and Parkinsons disease is also addressed. Adverse events and neutralizing antibodies formation after repeated BTX injections can occur. Since impaired neurological persons can have complex disabling feature, BTX treatment should be viewed as adjunct measure to other rehabilitative strategies that are based on the individuals residual ability and competence and targeted to achieve the best functional recovery. BTX therapy has high cost and transient effect, but its benefits outweigh these disadvantages. Future studies must clarify if this agent alone or adjunctive to other rehabilitative procedures works best on functional outcome.

AB - The botulinum toxins (BTX), type A and type B by blocking vesicle acetylcholine release at neuro-muscular and neuro-secretory junctions can result efficacious therapeutic agents for the treatment of numerous disorders in patients requiring neuro-rehabilitative intervention. Its use for the reduction of focal spasticity following stroke, brain injury, and cerebral palsy is provided. Although the reduction of spasticity is widely demonstrated with BTX type A injection, its impact on the improvement of dexterity and functional outcome remains controversial. The use of BTX for the rehabilitation of children with obstetrical brachial plexus palsy and in treating sialorrhea which can complicate the course of some severe neurological diseases such as amyotrophic lateral sclerosis and Parkinsons disease is also addressed. Adverse events and neutralizing antibodies formation after repeated BTX injections can occur. Since impaired neurological persons can have complex disabling feature, BTX treatment should be viewed as adjunct measure to other rehabilitative strategies that are based on the individuals residual ability and competence and targeted to achieve the best functional recovery. BTX therapy has high cost and transient effect, but its benefits outweigh these disadvantages. Future studies must clarify if this agent alone or adjunctive to other rehabilitative procedures works best on functional outcome.

UR - http://www.scopus.com/inward/record.url?scp=81555221758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81555221758&partnerID=8YFLogxK

U2 - 10.1155/2012/802893

DO - 10.1155/2012/802893

M3 - Article

C2 - 21941544

AN - SCOPUS:81555221758

VL - 2012

JO - Journal of Toxicology

JF - Journal of Toxicology

SN - 1687-8191

M1 - 802893

ER -